New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ABBV;ABT;ALJ;ALDW;FB;WGP;WES;LRCX;WHF From The Last 14 Days
Check below for free stories on ABBV;ABT;ALJ;ALDW;FB;WGP;WES;LRCX;WHF the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | all recent news | >>
September 15, 2014
06:14 EDTFBFacebook implied volatility of 27 at lower end of index mean range
Subscribe for More Information
September 14, 2014
13:30 EDTABTAbbott announces positive one-year clinical results from ABSORB II
Subscribe for More Information
12:51 EDTLRCXLam Research shares could return 20%, Barron's says
Lam Research could rise to $86.00 in a year, driven by market share, and could return more than 20%, including dividends, Barron's contends in a feature article. Reference Link
September 12, 2014
07:32 EDTABBVBiogen, AbbVie announce ZINBRYTA DECIDE Phase 3 study results
Biogen (BIIB) and AbbVie (ABBV) announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA, dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis compared to AVONEX. These results are being presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis. Patients on ZINBRYTA demonstrated a statistically significant 45% reduction in annualized relapse rate compared to patients treated with AVONEX. Based on the efficacy and safety data from the ZINBRYTA clinical development program, Biogen Idec and AbbVie plan to file marketing applications for ZINBRYTA with regulatory authorities during 1H15.
06:17 EDTFBFacebook looks to lure YouTube's video content providers, WSJ reports
Subscribe for More Information
September 11, 2014
13:41 EDTABTAbbott announces new $3B share repurchase program
Subscribe for More Information
07:02 EDTFBFacebook Q3 estimates have potential upside, says Citigroup
Subscribe for More Information
06:02 EDTFBFacebook implied volatility of 26 at lower end of index mean range
Subscribe for More Information
05:34 EDTABBVAbbVie reports Humira Phase 3 trial meets primary endpoint
Subscribe for More Information
September 10, 2014
12:04 EDTFBFacebook testing tool that lets users schedule post deletions, The Next Web says
Facebook is testing a tool that will allow users to create self-destructing Facebook posts that disappear after a specified period of time, The Next Web reports. A spokesperson has confirmed, saying "We’re running a small pilot of a feature on Facebook for iOS that lets people schedule deletion of their posts in advance." Reference Link
10:24 EDTABBVEnanta announces AbbVie initiated Phase 2b trial with ABT-493
Enanta (ENTA) announced that AbbVie (ABBV) initiated a phase 2b clinical study with ABT-493, Enanta’s next-generation protease inhibitor. ABT-493 is the second clinical-stage protease inhibitor candidate developed within the Enanta-AbbVie collaboration. The phase 2b study being conducted by AbbVie will evaluate the safety and efficacy of ABT-493 co-administered with ABT-530 in HCV patients. AbbVie has informed Enanta that results from this trial are expected in 2015 and AbbVie plans to start phase 3 development of the combination next year.
08:10 EDTALJAlon USA Energy receives approval for Bakersfield rail and refinery project
Subscribe for More Information
September 9, 2014
14:32 EDTFBApple shows Facebook, Twitter apps on Apple Watch
09:36 EDTFBActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL KNDI NFLX YHOO TWTR TSLA C BAC FB MCD
07:17 EDTFBThe Wireless Association to hold a conference
Subscribe for More Information
06:42 EDTABTLew expects to make decision on combating inversion deals soon, NY Times reports
Subscribe for More Information
September 8, 2014
14:00 EDTFBFacebook averages more than 1B video views per day, introducing video views
Subscribe for More Information
12:40 EDTABBVFTC sues AbbVie over blocking of AndroGel generics
The Federal Trade Commission has filed a complaint in federal district court charging several pharmaceutical companies with "illegally blocking American consumers’ access to lower-cost versions of the blockbuster drug AndroGel." The FTC's complaint alleges that AbbVie (ABBV) and its partner Besins Healthcare filed baseless patent infringement lawsuits against potential generic competitors to delay the introduction of lower-priced versions of the testosterone replacement drug AndroGel. While the lawsuits were pending, AbbVie then entered into an anticompetitive pay-for-delay settlement agreement with Teva Pharmaceuticals (TEVA) to further delay generic drug competition, the FTC claims. Reference Link
10:00 EDTFBFacebook may soon enter China, DoNews reports
Subscribe for More Information
09:40 EDTFBActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL TWTR TSLA YHOO BAC FB MSFT NFLX GILD MCD
<< 1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use